Focus Partners Advisor Solutions LLC Acquires 1,494 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Focus Partners Advisor Solutions LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,403 shares of the biopharmaceutical company’s stock after acquiring an additional 1,494 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Regeneron Pharmaceuticals were worth $3,399,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. Waddell & Associates LLC raised its holdings in shares of Regeneron Pharmaceuticals by 63.7% during the 4th quarter. Waddell & Associates LLC now owns 1,185 shares of the biopharmaceutical company’s stock valued at $915,000 after purchasing an additional 461 shares in the last quarter. Cerity Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals by 66.7% during the 4th quarter. Cerity Partners LLC now owns 34,227 shares of the biopharmaceutical company’s stock valued at $26,418,000 after purchasing an additional 13,693 shares in the last quarter. Orion Investment Co raised its holdings in shares of Regeneron Pharmaceuticals by 0.6% during the 4th quarter. Orion Investment Co now owns 30,812 shares of the biopharmaceutical company’s stock valued at $23,783,000 after purchasing an additional 175 shares in the last quarter. Franklin Resources Inc. raised its holdings in Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after buying an additional 106,861 shares in the last quarter. Finally, Erste Asset Management GmbH raised its holdings in Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Erste Asset Management GmbH now owns 52,049 shares of the biopharmaceutical company’s stock valued at $40,471,000 after buying an additional 3,313 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Guggenheim raised their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Canaccord Genuity Group cut their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ:REGN opened at $616.18 on Wednesday. The company has a market cap of $65.14 billion, a P/E ratio of 15.01, a P/E/G ratio of 1.34 and a beta of 0.25. The stock’s 50-day moving average is $701.59 and its 200-day moving average is $741.02. Regeneron Pharmaceuticals, Inc. has a 52-week low of $503.25 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the business posted $8.22 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.